More on ANAB

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (6.5 Score)
- Holders

Upcoming Events

- Earnings (11/4/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Anaptysbio (NQ:ANAB)
Delayed: 48.73 +0.63 (1.31%)
Prev. Close $48.10  
Open$48.19 
52 Wk High$ 
52 Wk Low$ 
Day High$48.89 
Day Low$47.05 
P/E N/A  
EPS$ 
Volume468,215 

Friends, Peers and Foes (?): TRAX, VNDA, ABBV, AMGN, BMY (more...)

Oct 19, 2026 02:21 PM FDA approves Jemperli for rectal cancer, benefiting AnaptysBio
Oct 19, 2026 02:18 PM Jemperli (dostarlimab) Approved in the U.S. as First and Only Immunotherapy for Adults with MSI-H/dMMR Locally Advanced Rectal Cancer
Oct 2, 2026 05:48 PM Form 4 ANAPTYSBIO, INC For: Oct 01 Filed by: RENTON HOLLINGS
Oct 1, 2026 04:08 PM Form 144 ANAPTYSBIO, INC Filed by: RENTON HOLLINGS
Sep 30, 2026 09:09 AM AnaptysBio (ANAB) PT Lowered to $60 at JPMorgan
Sep 22, 2026 07:54 AM AnaptysBio, Inc. (ANAB) Tops Q2 EPS by 524c
Sep 22, 2026 07:36 AM H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)
Sep 21, 2026 04:24 PM Form 10-KT ANAPTYSBIO, INC For: Jun 30
Sep 21, 2026 04:20 PM Form 8-K ANAPTYSBIO, INC For: Sep 21
Sep 21, 2026 04:15 PM Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update
View All Articles

Entities mentioned with ANAB

View All Entities